CSL Vifor and Travere Therapeutics (TVTX) announced that the European Commission has approved the conversion of the conditional marketing approval into a standard marketing authorization for Filspari for the treatment of adults with primary IgA nephropathy with a urine protein excretion of 1.0 g/day. Standard MA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- TVTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tax Day 2025 IRS Payment: Stocks to Consider Buying With the Refund
- Travere Therapeutics price target lowered to $30 from $32 at Scotiabank
- Travere Therapeutics price target raised to $47 from $45 at Canaccord
- Travere Therapeutics price target lowered to $27 from $31 at BofA